LAEVOROC ONCOLOGY
Laevoroc Oncology is to leverage word-class technologies, extensive R&D, and commercial experience to approach innovation in cancer therapeutics in a way that combines the pragmatic with the visionary.
LAEVOROC ONCOLOGY
Social Links:
Industry:
Medical Therapeutics
Founded:
2019-01-01
Address:
Hünenberg, Zug, Switzerland
Country:
Switzerland
Website Url:
http://www.laevoroc.com
Total Employee:
1+
Status:
Active
Email Addresses:
[email protected]
Total Funding:
1.1 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SSL By Default Google Font API Apple Mobile Web Clips Icon WordPress Content Delivery Network Font Awesome Wordpress Plugins Sitelinks Search Box
Similar Organizations
Aulos Bioscience
Aulos Bioscience is dedicated to revolutionizing patient care in cancer with highly differentiated immuno-oncology therapeutics.
Scholar Rock
Scholar Rock is a biopharmaceutical company that develops and discovers new medicines and treatments for the serious diseases.
Slingshot Biosciences
Slingshot Biosciences develops next-generation synthetic cells for diagnostics and therapeutics.
Theolytics
Theolytics is a pre-clinical stage biotechnology company developing next-generation oncolytic viral therapies.
Vetsource
Vetsource provides comprehensive solutions to those who care for pets - veterinarians and pet owners.
Current Employees Featured
Founder
Official Site Inspections
http://www.laevoroc.com Semrush global rank: 5.48 M Semrush visits lastest month: 1.56 K
- Host name: 99.0.153.160.host.secureserver.net
- IP address: 160.153.0.99
- Location: Scottsdale United States
- Latitude: 33.6013
- Longitude: -111.8867
- Metro Code: 753
- Timezone: America/Phoenix
- Postal: 85260
More informations about "Laevoroc Oncology"
LAEVOROC Oncology AG
Leveraging ground-breaking technology to bring game-changing therapies to patients living with cancer.See details»
Laevoroc Oncology - Crunchbase Company Profile & Funding
Laevoroc Oncology is to leverage word-class technologies, extensive R&D, and experience to approach innovation in cancer therapeutics.See details»
Laevoroc Immunology - Crunchbase Company Profile & Funding
Laevoroc Immunology pioneers a groundbreaking therapy for relapsed leukemia post stem cell transplant.See details»
Helix Biopharma Corp. Enters into Non-Binding Letter of Intent to ...
Nov 13, 2024 Toronto, Ontario – Helix BioPharma Corp. (TSX: “HBP”, OTC PINK: “HBPCD”, FRANKFURT: “HBP020241113_Laevoroc LOI_Final”) (“Helix” or the “Company), a clinical …See details»
Laevoroc Oncology - PitchBook
May 11, 2021 Information on valuation, funding, cap tables, investors, and executives for Laevoroc Oncology. Use the PitchBook Platform to explore the full profile.See details»
Laevoroc Oncology Company Profile - Office Locations ... - Craft
Laevoroc Oncology has 5 employees at their 1 location and $1.1 m in total funding,. See insights on Laevoroc Oncology including office locations, competitors, revenue, financials, executives, …See details»
Laevoroc Oncology Launches WithThree-Pronged Strategy
Mar 18, 2022 Laevoroc Chemotherapy will develop a new oral gemcitabine prodrug, LR 06B, aiming to make a positive impact on health equity and quality of care for cancer patients …See details»
Laevoroc Oncology - CipherBio
Explore Laevoroc Oncology's investment information, scientific platforms, therapeutic approaches, indications and more here!See details»
Laevoroc Oncology AG (Laevoroc Oncology AG) - 药物管线_专利_ …
Laevoroc acquired the commercial rights to LR 09 for new indications in 2021. References (1) (2) -Ends- About Laevoroc Immunology Laevoroc Immunology is a Swiss immuno-oncology …See details»
Laevoroc Oncology Emerges from stealth mode announcing seed...
Zug, Switzerland, 11 May 2021: Laevoroc Oncology (‘Laevoroc’ or ‘the company’), a privately owned, Swiss oncology development group of companies, launched today announcing …See details»
Laevoroc Oncology - Funding, Financials, Valuation & Investors
Laevoroc Oncology is to leverage word-class technologies, extensive R&D, and experience to approach innovation in cancer therapeutics.See details»
Over USD 1.1 million seed capital for Laevoroc Oncology
May 21, 2021 Emerging from stealth mode, Zug based Laevoroc Oncology has completed the seed round, raising over USD 1.1 million from private and individual investors. The company …See details»
Laevoroc Immunology - Oncology Assets - Crunchbase
Laevoroc Immunology - Oncology Assets is a unit of Laevoroc Immunology.See details»
Laeverdoc (fka TNT Medical) - VentureRadar
Laevoroc Neuro-Oncology is the core of our company and will build a pipeline of innovative drugs addressing brain cancers. Right now, we are progressing LR 02 (a highly selective and potent …See details»
Helix Biopharma Corp. Enters into Non-Binding Letter of Intent to ...
Nov 13, 2024 Laevoroc Chemotherapy’s asset is a novel, oral formulation of gemcitabine designed to be used as combination or maintenance therapy for high-prevalence, hard-to-treat …See details»
Laevoroc Immunology AG - Drug pipelines, Patents, Clinical trials
Explore Laevoroc Immunology AG with its drug pipeline, therapeutic area, technology platform, .See details»
Laevoroc Chemotherapy AG (Laevoroc Chemotherapy AG) - 药物 …
了解Laevoroc Chemotherapy AG (Laevoroc Chemotherapy AG)公司的药物管线，治疗领域，技术平台，以及它的。See details»
Laevoroc Oncology pushes for relapsed leukemia cure
Dec 8, 2022 Laevoroc Oncology’s co-founder and CEO, Thomas Mehrling, said: “We are delighted to have achieved this discovery with UCLA, which supports our vision for LR 09 to …See details»
Laevoroc Oncology Launches WithThree-Pronged Strategy
Jul 7, 2021 Laevoroc Immunology is repurposing the small molecule drug, Ulodesine, originally developed for the treatment of gout, as an oral immuno-oncology agent to initiate graft-versus …See details»
Laevoroc Oncology Launches WithThree-Pronged Strategy
May 24, 2021 In Vivo interview with our CEO, Thomas Mehrling, where he presented Laevoroc Oncology’s three-pronged strategy to off-set risk and provide greater choice to future partners …See details»